Apogee Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Apogee Therapeutics, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation advisory vote.
NASDAQ
DEFA14A: Apogee Therapeutics Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote
Apogee Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, with voting open until June 16, 2025, covering director elections, auditor ratification, and executive compensation advisory vote frequency.
NASDAQ
Apogee Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, featuring proposals for director elections, auditor ratification, and executive compensation advisory vote.
NASDAQ
Apogee Therapeutics has appointed Lisa Bollinger, M.D., a seasoned drug development expert, to its Board of Directors, effective May 28, 2024.
NASDAQ
Apogee Therapeutics has scheduled its 2024 Annual Meeting for June 5, 2024, and is soliciting votes on key proposals including the election of directors and ratification of the company's independent auditor.
NASDAQ
Apogee Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to vote on director elections, auditor ratification, and an option grant to a director.